Frontiers journals are at the top of citation and impact metrics

Perspective ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Cardiovasc. Med. | doi: 10.3389/fcvm.2018.00177

Targeting inflammation to prevent cardiovascular disease in chronic rheumatic diseases: myth or reality?

 Elena Bartoloni1,  Alessia Alunno1, Valentina Valentini1, Filippo Luccioli1, Eleonora Valentini1, Giuliana Maria Concetta La Paglia1,  Maria Comasia Leone1,  Giacomo Cafaro1, Elisa Marcucci1 and  Roberto Gerli1*
  • 1University of Perugia, Italy

Evidence for increased risk of cardiovascular morbidity and mortality in chronic inflammatory rheumatic diseases has accumulated during the last years. Traditional cardiovascular risk factors contribute in part to the excess of cardiovascular risk in these patients and several mechanisms, including precocious acceleration of subclinical atherosclerotic damage, inflammation and immune system deregulation factors, have been demonstrated to strictly interplay in the induction and progression of atherosclerosis. In this setting, chronic inflammation is a cornerstone of rheumatic disease pathogenesis and exerts also a pivotal role in all stages of atherosclerotic damage.
The strict link between inflammation and atherosclerosis suggests that cardiovascular risk may be reduced by rheumatic disease activity control. There are data to suggest that biologic therapies, in particular TNFα antagonists, may improve surrogate markers of cadiovascualr disease and reduce CV adverse outcome. Thus, abrogation of inflammation is considered an important outcome for achieving not only control of rheumatic disease, but also reduction of cardiovascular risk. However, the actual effect of anti-rheumatic therapies on atherosclerosis progression and CV outcome in these patients is rather uncertain due to great literature inconsistency. In this paper, we will summarize some of the main mechanisms linking the inflammatory pathogenic background underlying rheumatic diseases and the vascular damage observed in these patiens, with a particular emphasis on the pathways targeted by currently available therapies. Moreover, we will analyze current evidence on the potential atheroprotective effects of these treatments on cardiovascular outcome pointing out still unresolved questions.

Keywords: Rheumatic disease, Inflammation, cardiovascular disease, Atherosclerosis, Biologic therapies, rheumatoid arhritis, psoriatic arthritis, Ankylosing spondilytis

Received: 17 Sep 2018; Accepted: 29 Nov 2018.

Edited by:

Pietro Enea Lazzerini, Università degli Studi di Siena, Italy

Reviewed by:

Teresa Padro, Sant Pau Institute for Biomedical Research, Spain
Michael T. Nurmohamed, VU University Medical Center, Netherlands
Piero Ruscitti, University of L'Aquila, Italy  

Copyright: © 2018 Bartoloni, Alunno, Valentini, Luccioli, Valentini, La Paglia, Leone, Cafaro, Marcucci and Gerli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Prof. Roberto Gerli, University of Perugia, Perugia, Italy, roberto.gerli@unipg.it